A detailed history of Black Rock Inc. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 756,736 shares of CUE stock, worth $824,842. This represents 0.0% of its overall portfolio holdings.

Number of Shares
756,736
Previous 2,244,103 66.28%
Holding current value
$824,842
Previous $4.24 Million 77.88%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.24 - $2.18 $1.84 Million - $3.24 Million
-1,487,367 Reduced 66.28%
756,736 $938,000
Q1 2024

May 10, 2024

SELL
$1.77 - $3.09 $167,551 - $292,505
-94,662 Reduced 4.05%
2,244,103 $4.24 Million
Q4 2023

Feb 13, 2024

BUY
$1.72 - $3.1 $360,881 - $650,426
209,815 Added 9.86%
2,338,765 $6.17 Million
Q3 2023

Nov 13, 2023

BUY
$2.23 - $4.69 $140,213 - $294,888
62,876 Added 3.04%
2,128,950 $4.9 Million
Q2 2023

Aug 11, 2023

BUY
$3.11 - $4.91 $4.36 Million - $6.88 Million
1,401,648 Added 210.96%
2,066,074 $7.54 Million
Q1 2023

May 12, 2023

SELL
$2.41 - $3.74 $90,989 - $141,203
-37,755 Reduced 5.38%
664,426 $2.37 Million
Q4 2022

Feb 13, 2023

SELL
$2.39 - $3.95 $182,899 - $302,281
-76,527 Reduced 9.83%
702,181 $2 Million
Q3 2022

Nov 14, 2022

SELL
$2.23 - $3.37 $118,673 - $179,341
-53,217 Reduced 6.4%
778,708 $1.74 Million
Q2 2022

Aug 12, 2022

SELL
$2.49 - $5.92 $3.86 Million - $9.17 Million
-1,549,342 Reduced 65.06%
831,925 $2.07 Million
Q1 2022

May 12, 2022

BUY
$4.41 - $12.28 $401,301 - $1.12 Million
90,998 Added 3.97%
2,381,267 $11.6 Million
Q4 2021

Feb 10, 2022

BUY
$10.86 - $17.85 $1.41 Million - $2.32 Million
129,811 Added 6.01%
2,290,269 $25.9 Million
Q3 2021

Nov 09, 2021

BUY
$10.06 - $15.3 $117,299 - $178,398
11,660 Added 0.54%
2,160,458 $31.5 Million
Q2 2021

Aug 11, 2021

BUY
$10.9 - $14.53 $23.4 Million - $31.2 Million
2,148,798 New
2,148,798 $25 Million

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $38.6M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.